Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short Course ADT + SBRT for High Risk Prostate Cancer with Lower Risk ARTERA Scores
NCT07801664Phase 2Recruiting
- Sponsor
- NYU Langone Health
- Start
- Aug 2026
- Primary completion
- Aug 2028
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in prostate cancer (PCa), sponsored by NYU Langone Health. Primary endpoint: 5-Year Cumulative Incidence of Distant Metastases. Started Aug 2026; status: recruiting.
02
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT07801664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07801664.